These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29503734)

  • 1. Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial.
    Horinouchi H; Kubota K; Miyanaga A; Nakamichi S; Seike M; Gemma A; Yamane Y; Kurimoto F; Sakai H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T; Ohe Y
    ESMO Open; 2018; 3(1):e000288. PubMed ID: 29503734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.
    Horinouchi H; Kubota K; Itani H; Taniyama TK; Nakamichi S; Wakui H; Kanda S; Nokihara H; Yamamoto N; Sekine I; Tamura T
    Jpn J Clin Oncol; 2013 Nov; 43(11):1105-9. PubMed ID: 24006505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer.
    Sato J; Morikawa N; Nitanai H; Nagashima H; Nihei S; Yamauti K; Kudo K
    J Pharm Health Care Sci; 2016; 2():6. PubMed ID: 26949541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method.
    Saito Y; Takekuma Y; Kobayashi M; Shinagawa N; Noguchi T; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Sugawara M
    Anticancer Res; 2022 Jun; 42(6):3185-3193. PubMed ID: 35641251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
    Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Short Hydration on Cisplatin-Induced Nephrotoxicity in Cancer Patients: A Retrospective Study.
    Ashrafi F; Ebrahimi Z; Nematbakhsh M
    Int J Hematol Oncol Stem Cell Res; 2017 Oct; 11(4):262-267. PubMed ID: 29340120
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
    Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
    Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety Assessment of a Short Hydration Regimen for Outpatient Cisplatin-Based Chemotherapy].
    Yoshida H; Kimata T; Suzuki M; Uchida T; Yamamuro O
    Gan To Kagaku Ryoho; 2016 Sep; 43(9):1081-5. PubMed ID: 27628548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
    Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
    Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
    Sato J; Kudo K; Hino K; Takahashi K
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
    Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
    Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies.
    Tanaka M; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ohe Y
    ESMO Open; 2018; 3(4):e000342. PubMed ID: 29765771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.
    Longo F; Mansueto G; Lapadula V; Stumbo L; Del Bene G; Adua D; De Filippis L; Bonizzoni E; Quadrini S
    Int J Clin Pract; 2012 Aug; 66(8):753-757. PubMed ID: 22805267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
    Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
    Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cisplatin administration for outpatients with short hydration of less than four hours].
    Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.